Pappas Todd C, Bader Andreas G, Andruss Bernard F, Brown David, Ford Lance P
Asuragen, Inc., 2150 Woodward Street, Suite 100, Austin, TX 78744, USA.
Expert Opin Ther Targets. 2008 Jan;12(1):115-27. doi: 10.1517/14728222.12.1.115.
Small interfering RNAs (siRNA) and microRNAs (miRNA) are gaining considerable attention in the pharmaceutical and biotechnology industries, as research has revealed their likely clinical and agricultural applications. The capacity of siRNAs to dramatically and specifically reduce the expression of targeted genes has spawned multiple clinical trials to establish the therapeutic potential of small RNAs targeting viral, cancer and other disease-related genes. The successful application of siRNAs will enable the development of therapeutic applications based on miRNAs that have been observed to contribute to a variety of human diseases. This article reviews advances that have been made to apply small RNAs as therapeutics.
小干扰RNA(siRNA)和微小RNA(miRNA)在制药和生物技术行业正受到广泛关注,因为研究已经揭示了它们在临床和农业方面可能的应用。siRNA能够显著且特异性地降低靶向基因的表达,这催生了多项临床试验,以确定靶向病毒、癌症和其他疾病相关基因的小RNA的治疗潜力。siRNA的成功应用将推动基于miRNA的治疗应用的发展,因为已观察到miRNA与多种人类疾病有关。本文综述了将小RNA用作治疗药物所取得的进展。